Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01783119

Acronym

AVIUC

Enrollment

Registered

2013-02-04

Start date

2012-08-31

Completion date

2014-12-31

Last updated

2013-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

Ulcerative Colitis, Aloe Vera

Brief summary

The Ulcerative Colitis (UC) belongs to the group of diseases called Inflammatory Bowel Disease (IBD) which is characterized by a chronic ulceration of the colon. The conventional treatment can have adverse effects and does not guarantee effectiveness in some patients requiring aggressive therapy using adjuvant therapy Aloe vera has been shown to have a beneficial effect in different disease, and have an anti-inflammatory effect in UC patients. Objective: Measuring the effect of the consumption of 200 ml of aloe vera gel daily for a period of three months, in the degree of inflammation in patients with mild UC based on Mayo scale and quantification of IL-6 in the colonic mucosa.

Interventions

DIETARY_SUPPLEMENTAloe Barbadensis Miller

DIETARY_SUPPLEMENTplacebo water

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 59 Years

Healthy volunteers

Inclusion criteria

* Patients with confirmed diagnosis by histopathology of Ulcerative Colitis with mild activity level clinical, Endoscopic and histological. * Extent of disease: pancolitis, ulcerative proctitis and left. * Being treated with 5 - aminosalicylates (5-ASA). * Belonging to the National Institute of Medical Sciences and Nutrition Salvador Zubirán. * Signed informed consent.

Exclusion criteria

* Autoimmune diseases (lupus, HIV, cancer and any hepatitis). * Another type of colitis (indeterminate, infectious drug and Crohn's Disease. * Previous total colectomy. * Body mass index less than 19.9 kg/m2 or greater than 40 kg/m2. * Patients in remission histology, clinical and endoscopic. * Under treatment with steroids, azathioprine, diuretics and anticoagulants. * Use Aloe Vera or some natural therapy.

Design outcomes

Primary

Measure	Time frame	Description
Full Mayo Score	3 months	—
Interleukine - 6	3 months	Quantification in mucosal Biopsy

Countries

Mexico

Contacts

Primary ContactJesús K. Yamamoto-Furusho, PhD,MD

kazuofurusho@hotmail.com+5554870900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026